Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline

Bedaquiline is a novel drug approved in 2012 by the FDA for treatment of drug-resistant tuberculosis (TB). Although it shows high efficacy towards drug-resistant forms of TB, its use has been limited by the potential for significant side effects. In particular, bedaquiline is a very lipophilic compo...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Peter J., Conole, Daniel, Sutherland, Hamish S., Blaser, Adrian, Tong, Amy S.T., Cooper, Christopher B., Upton, Anna M., Palmer, Brian D., Denny, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144385/
https://www.ncbi.nlm.nih.gov/pubmed/32245020
http://dx.doi.org/10.3390/molecules25061423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144385/
https://www.ncbi.nlm.nih.gov/pubmed/32245020
http://dx.doi.org/10.3390/molecules25061423

Ejemplares similares